Pharsight

Juluca is owned by Viiv Hlthcare.

Juluca contains Dolutegravir Sodium; Rilpivirine Hydrochloride.

Juluca has a total of 6 drug patents out of which 1 drug patent has expired.

Expired drug patents of Juluca are:

Juluca was authorised for market use on 21 November, 2017.

Juluca is available in tablet;oral dosage forms.

Juluca can be used as treatment of hiv infection.

The generics of Juluca are possible to be released after 24 January, 2031.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551	VIIV HLTHCARE	HIV inhibiting pyrimidines derivatives	Apr, 2023 (2 months from now)
US7125879	VIIV HLTHCARE	HIV inhibiting pyrimidines derivatives	Apr, 2025 (2 years from now)
US8129385	VIIV HLTHCARE	Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness	Oct, 2027 (4 years from now)
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (6 years from now)
US10426780	VIIV HLTHCARE	Antiviral therapy	Jan, 2031 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629	VIIV HLTHCARE	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile	Aug, 2022 (5 months ago)